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To determine independent prognostic factors for the survival of patients with endometrial stromal sarcoma (ESS), data were
abstracted from the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute from 1988 to 2003.
Kaplan–Meier and Cox proportional hazards models were used for analyses. Of 831 women diagnosed with ESS, the median age
was 52 years (range: 17–96 years). In total, 59.9% had stage I, 5.1% stage II, 14.9% stage III, and 20.1% had stage IV disease. Overall,
13.0, 36.1, and 34.7% presented with grades 1, 2, and 3, respectively. Patients with stage I–II vs III–IV disease had 5 years DSS of 89.3%
vs 50.3% (Po0.001) and those with grades 1, 2, and 3 cancers had survivals of 91.4, 95.4, and 42.1% (Po0.001). In multivariate
analysis, older patients, black race, advanced stage, higher grade, lack of primary surgery, and nodal metastasis were independent
prognostic factors for poorer survival. In younger women (o50 years) with stage I–II disease, ovarian-sparing procedures did not
adversely impact survival (91.9 vs 96.2%; P¼0.1). Age, race, primary surgery, stage, and grade are important prognostic factors for
ESS. Excellent survival in patients with grade 1 and 2 disease of all stages supports the concept that these tumors are significantly
different from grade 3 tumors. Ovarian-sparing surgeries may be considered in younger patients with early-stage disease.
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Endometrial stromal sarcomas (ESSs) are rare tumors of the uterus
accounting for 0.2–1% of all uterine malignancies and approxi-
mately 6–20% of all uterine sarcomas (Koss et al, 1965; Harlow
et al, 1986; Echt et al, 1990; Larson et al, 1990). Given the rarity of
ESS, there are limited reports in the literature that have evaluated
the prognostic factors of patients with this tumor. On account of
significant differences in the clinical behaviour of ESS patients,
Norris and Taylor first described the prognostic significance of
histologic grade in ESS, and their findings have been subsequently
confirmed by others (Norris and Taylor, 1966; Pautier et al, 2000;
Leath et al, 2007). Furthermore, as high-grade ESS lack specific
differentiation, recent modifications to pathologic classifications of
uterine sarcoma have been recommended to rename high-grade
ESS as undifferentiated endometrial sarcoma (Jaffe et al, 2001;
Moinfar et al, 2007).
Optimal therapy of ESS is not well established. The standard
surgical procedure has included a total abdominal hysterectomy,
bilateral salpingo-oophorectomy, and radical cytoreductive sur-
gery of extra-uterine disease (Gadducci et al, 1996). Moreover,
despite traditional recommendations to include bilateral salpingo-
oophorectomy in the primary surgical management of ESS, some
investigators have advocated preserving ovarian function, parti-
cularly in younger women (Gadducci et al, 1996; Chu et al, 2003; Li
et al, 2005; Amant et al, 2007). The role of pelvic and para-aortic
lymphadenectomy, and adjuvant therapy with radiation therapy,
chemotherapy, or hormonal treatment remains controversial. Most
of the earlier studies have been limited by a small number of
patients from academic institutions with associated biases (Echt
et al, 1990; Haberal et al, 2003; Denschlag et al, 2007; Leath et al,
2007). In addition, there are no large studies that have investigated
the potential risk of ovarian preservation in young patients with
early-stage disease.
In this large population-based study of 831 patients, we
examined the demographic and clinico-pathologic prognostic
factors associated with disease-specific survival (DSS) in ESS. In
addition, the role of lymphadenectomy, adjuvant radiation
therapy, and oophorectomy was analyzed.
MATERIALS AND METHODS
Demographic, clinico-pathologic variables, treatment data,
and survival information of women diagnosed with ESS were
extracted from the Surveillance, Epidemiology, and End Results
(SEER) database of the United States National Cancer Institute
for the 15-year period from 1 January 1988 to 31 December
2003. Data are reported from population-based registries that
represent approximately 26% of the U.S. population including the
states of Utah, Hawaii, Iowa, New Mexico, Connecticut, Alaska
Native, and the metropolitan regions of Detroit, San Francisco-
Oakland, Seattle-Puget Sound, Atlanta, San Jose-Monterey,
Los Angeles, and rural Georgia. The histology code used was
8930 for ESS. Although the database coded grade of disease as 1, 2,
3 and 4, we elected to combine grades 3 and 4 as grade 3 disease
given the similarity of the two groups.
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sTable 1 Demographic and clinico-pathologic characteristics (n¼831)
Characteristics n %
Age at diagnosis (years)
Median age (range) 52 (17–96)
p52 years 432 52.0
452 years 399 48.0
Year of diagnosis
1988–1992 150 18.0
1993–1997 284 34.2
1998–2003 397 47.8
Race
White 553 66.5
Black 114 13.7
Hispanic 82 9.9
Asian 70 8.4
Other 12 1.4
Stage
I 498 59.9
II 42 5.1
III 124 14.9
IV 167 20.1
Grade
1 108 13.0
2 300 36.1
3 288 34.7
Unknown 135 16.2
Table 2 Treatment characteristics (n¼831)
Characteristics n %
Surgery
Yes
a 775 93.3
No 56 6.7
Lymphadenectomy
Yes 282 33.9
Positive 28 9.9
b
Negative 245 86.9
b
Unknown 9 3.2
b
No 543 65.3
Unknown 6 0.7
Oophorectomy
Yes 483 58.1
No 290 34.9
Unknown 58 7.0
Age o50 years, stage I–II
Yes 155 64.6
c
No 85 35.4
c
Radiation
Yes 205 24.7
No 611 73.5
Unknown 15 1.8
aPrimary hysterectomy.
bPercent of those undergoing lymphadenectomy.
cPercent of
those o50 years, stage I–II.
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Figure 1 Kaplan–Meier disease-specific survival based on (A) age (Po0.001), (B) race (P¼0.001), (C) surgery (Po0.001), (D) stage (Po0.001),
(E) grade (Po0.001), (F) nodal metastasis (Po0.001), and (G) oophorectomy in younger women (o50 years) with stage I–II disease (P¼0.1).
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sKaplan–Meier models were used to estimate 5-year DSS.
Variables examined included age, race, stage, grade, primary
surgery, and presence of nodal metastasis, oophorectomy, and
adjuvant radiation treatment. All factors that were significant in
univariate analyses were tested in the multivariable model. The
Cox proportional hazards model was used to identify independent
predictors of survival. All P-values reported are two-tailed, and a
P-value of less than 0.05 was considered to be statistically
significant.
RESULTS
Of 831 women with ESS, the median age at diagnosis was 52 years
(range: 17–96 years). Demographic characteristics of these
patients are presented in Table 1. The majority (59.9%) had stage
I disease, 5.1% stage II, 14.9% stage III, and 20.1% had stage IV
disease. Grades 1, 2, and 3 comprised 13.0, 36.1, and 34.7% of
cases, respectively.
Analysis of surgical treatment found that 775 (93.3%) women
underwent a hysterectomy; 282 (33.9%) also had a lymphadenec-
tomy, and 28 (9.9%) women were found to have nodal metastases.
Moreover, the rate of lymphadenectomy in those women 50 years
and younger vs older than 50 years was 32.2 vs 35.9%, respectively.
Oophorectomy was performed in 483 (58.1%) cases. In addition,
24.7% of patients underwent adjuvant radiotherapy. Table 1
provides further details of treatment characteristics. Of patients
with grades 1, 2, and 3 disease, 33 (11.7%), 79 (28.0%), and 127
(45.0%) underwent lymph node dissections, of which 2 (6.1%), 7
(8.9%), and 16 (12.6%) had nodal metastases. Lastly, approxi-
mately 6.7% of the patients did not undergo primary surgery. Of
these 56 patients, the median age was 68.8 years of age compared
with only 51 years in those who underwent surgery. In addition,
the proportion of advanced stage disease was higher in those
without surgery, 82.1 vs 31.6%.
The 5-year DSS for the entire cohort was 76.2%. The 5-year DSS
of younger patients (o52 years) was significantly higher compared
with older women (85.9 vs 64.7%, Po0.001) (Table 2). Blacks had a
worse DSS compared with other races (62.5 vs 78.1%; P¼0.001).
Those who underwent primary hysterectomy had a significant
benefit over those who did not (78.5 vs 42.4%; Po0.001).
Moreover, the 5-year DSS of those with stage I–II disease was 89
vs 50.3% in those with stages III–IV disease (Po0.001). Those
with grades 1, 2, and 3 disease had 5-year DSSs of 91.4, 95.4, and
42.1%, respectively (Po0.001) (Figure 1).
In the overall study group, there was no difference in 5-year DSS
in those who underwent oophorectomy vs ovarian-sparing
procedures (P¼0.06) (Table 2). Similarly, in the subset of younger
women (o50 years) with stage I–II disease, those who underwent
ovarian-sparing procedures had a similar survival compared with
those who underwent oophorectomies (96.2 vs 91.1%; P¼0.1).
However, the exact number of patients who may have undergone
adnexal surgery before their cancer diagnosis is not reported.
Furthermore, lymphadenectomy and adjuvant treatment with
radiation therapy had no demonstrable impact on overall survival.
Factors found to be significant in univariate analysis were then
analyzed using a Cox proportional hazards model to determine
independent predictors of DSS. On multivariate analysis, older age
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Figure 1 Continued.
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sat diagnosis, black race, no surgery, advanced stage, and higher
grade of disease were all independent predictors for poorer
survival (Tables 3 and 4).
DISCUSSION
As endometrial stromal sarcomas are rare uterine malignancies,
there are limited reports on their clinical behaviour and optimal
treatment strategies. Most of these studies involve case reports,
and retrospective case series by academic institutions with a small
number of patients accrued over long time periods. In addition,
others series have included additional histological subtypes of
uterine sarcomas. To our knowledge, this analysis is one of the
largest studies, including over 800 patients evaluated for prog-
nostic factors important in ESS patients.
Earlier studies on the importance of age in ESS have been
inconclusive. Denschlag et al (2007) reported on 28 patients with
ESS, and found overall better survival was significantly associated
with younger patient age. Similarly, Kokawa et al (2006) showed
that younger age was an independent predictor of improved
survival in multivariate analysis of 15 cases of ESS. In contrast,
Nordal et al (1996) studied 48 patients with ESS and found that age
was not significantly correlated to survival. In this study of over
800 patients, patients p52 years had more than a 20% higher
5-year DSS compared with older patients. Moreover, age, as a
continuous variable remained a significant prognostic factor in
multivariate analysis.
In this analysis, our data also showed that blacks had a worse
DSS compared with all other racial groups after adjusting for other
prognostic factors. Racial and ethnic differences in treatment and
survival have been previously reported for several gynecologic
malignancies, including ovary and uterine cancers (Wingo et al,
1996; Madison et al, 1998; Maxwell et al, 2006; Morris et al, 2006;
Chan et al, 2008). In uterine sarcomas, Brooks et al (2004) found a
survival difference among racial groups, but this was no longer
present after adjusting for treatment differences. In this analysis,
we demonstrated that blacks with ESS have a poorer survival after
adjusting for surgery and adjuvant radiotherapy. Further studies
are warranted to identify the underlying cause for racial
differences in survival that cannot simply be explained by
treatment disparities.
Similar to other reports, our analysis found that stage and grade
were important predictors of overall improved survival (Echt et al,
1990; Kokawa et al, 2006; Denschlag et al, 2007). In our analysis,
stage I–II patients had a 5-year DSS of 89.3% compared with only
50.3% in stage III–IV disease. Grade has also long been recognized
as an important factor in ESS (Norris and Taylor, 1966; Pautier
et al, 2000; Haberal et al, 2003; Leath et al, 2007). In over 400
patients with grades 1 and 2 tumors in our study, the 5-year DSS
was more than 90% compared with only 42% in those with grade 3
tumors. These findings clearly support the hypothesis that high-
grade ESSs have a distinct biologic behaviour. This has also been
demonstrated by others (Gadducci et al, 1996; Leath et al, 2007). In
fact, there are some investigators who have recommended a
change in the classification of high-grade ESS to undifferentiated
endometrial sarcoma, as these tumors have distinct pathologic and
clinical properties compared with low-grade ESS. The 2003 World
Health Organization Classification of tumors employs this new
nomenclature, as does the current pathology literature, where the
term of ESS is used to describe low-grade stromal sarcomas only
(Jaffe et al, 2001; Moinfar et al, 2007).
Although standard therapy for ESS has included hysterectomy
and bilateral salpingo-oophorectomy, the additional extent of
surgery, especially the role of pelvic and para-aortic lymphade-
nectomy, remains controversial. In our study, the survival of those
who underwent a lymph node dissection was not significantly
different compared with those without lymph node dissection
(P¼0.351). However, it was interesting to note that nearly 10% of
those who underwent lymph node dissection were found to have
nodal metastases. Thus, it is important to perform lymphadenec-
tomy in ESS patients for both prognostic and treatment purposes
Table 3 Five-year disease-specific survival based on demographic and
clinico-pathologic prognostic factors (n¼831)
Characteristic % P-value
Overall 76.2 (±1.6)
Age at diagnosis (years) Po0.001
p52 85.9 (±1.8)
452 64.7 (±2.6)
Year of diagnosis P¼0.008
1988–1992 72.2 (±3.7)
a
1993–1997 83.9 (±2.2)
a
1998–2003 74.4 (±2.4)
a
Race P¼0.005
White 77.1 (±1.9)
Black 62.5 (±5.0)
Hispanic 79.6 (±4.7)
Asian 83.8 (±5.1)
Surgery Po0.001
Yes
b 78.5 (±1.6)
No 42.4 (±7.4)
Oophorectomy P¼0.06
Yes 78.1 (±2.0)
No 72.9 (±2.7)
Age o50 years, stage I–II P¼0.1
Yes 91.1 (±2.4)
No 96.2 (±2.1)
Stage Po0.001
I 91.7 (±1.3)
II 52.8 (±9.9)
III 61.5 (±4.8)
IV 41.0 (±4.4)
I–II 89.3 (±1.4) Po0.001
III–IV 50.3 (±3.3)
Grade Po0.001
1 91.4 (±3.0)
2 95.4 (±1.3)
3 42.1 (±3.8)
Lymphadenectomy P¼0.351
Yes 73.8 (±2.9)
No 77.6 (±1.9)
Nodal metastasis Po0.001
Positive 35.3 (±9.6)
Negative 80.1 (±2.8)
a3-year disease-specific survival.
bPrimary hysterectomy.
Table 4 Multivariate analysis
Prognostic factor Hazard ratio 95% Confidence interval P-value
Age at diagnosis
a 1.02 1.01–1.03 Po0.007
Race
b 1.70 1.18–2.45 P¼0.013
Surgery
c 0.36 0.23–0.57 Po0.001
Stage
d 1.99 1.73–2.28 Po0.001
Grade
e 9.04 5.77–14.17 Po0.001
aContinuous.
bNon-black vs black.
cNo primary hysterectomy vs primary hyster-
ectomy.
dI vs II vs III vs IV.
e1 vs 2 vs 3.
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sto direct adjuvant therapy. In addition, patients with positive
nodal metastasis at the time of lymphadenectomy had signi-
ficantly poorer survival (35.3%) compared with those that had
negative nodes (80.1%). Other reports have also suggested that the
rates of lymph node involvement in ESS may be higher than
expected (Goff et al, 1993; Reich et al, 2005; Riopel et al, 2005).
Therefore, lymph node dissection clearly provides prognostic
information and treatment guidance; however, the potential
therapeutic value of lymph node dissection remains to be
determined.
Similar to endometrioid uterine cancer, the standard recom-
mendations have included bilateral salpingo-oophorectomy in the
primary surgical management of ESS. This study showed that
ovarian-sparing surgeries in the subset of younger women
(o50years) with otherwise early-stage disease did not adversely
impact survival. Similarly, Li et al (2005) found that ovarian
preservation did not affect recurrence or survival in women with
stage I low-grade ESS. Similar findings were described by Amant
et al (2007) in a multicenter analysis of 34 women with ESS. In
stage I–II premenopausal women who underwent hysterectomy
with or without bilateral saplingo oophorectomy, 3 of 12 (25%)
and 1 of 6 (17%) recurred, respectively. Although the sample size
was too small to draw conclusions, ovarian preservation did not
seem to compromise outcomes. These results were also confirmed
by others (Gadducci et al, 1996; Chu et al, 2003). In contrast, in a
recent analysis of 53 patients, investigators found that ovarian
preservation resulted in higher recurrence rates of 9 of 9 patients
vs 10 of 44 (Po0.001) in those who had bilateral salpingo-
oophorectomy (Li et al, 2008). Although our data suggest that
ovarian-sparing surgeries may be considered in younger patients
with early-stage disease, it is important to note that the SEER data
do not include data on adnexal surgeries before cancer diagnosis.
Thus, these limitations may have influenced our results.
The strength of our study is the large number of patients, which
permitted subset analyses investigating the role of lymphadenec-
tomy and oophorectomy, as well as other prognostic factors, such
as age, race, and grade of disease. Moreover, the SEER database is
representative of the general patient population without associated
biases of case reports and studies from single academic institutions
that span over many years. Several studies have demonstrated the
accuracy of pathology from the SEER database (Glaser et al, 2001;
Field et al, 2004). There are, however, several limitations of this
study, including a lack of information regarding surgeon specialty,
residual disease or margin status after primary surgery, hormone
receptor status, sites of recurrence, earlier oophorectomy,
chemotherapy, hormonal treatment or combined treatments.
In summary, the results of this study of 831 women with ESSs
showed that age, race, stage, and grade of disease are important
independent prognostic factors for survival. The survival of more
than 90% in patients with grades 1 and 2 disease compared with
only 42% in those with grade 3 disease supports the concept that
low-grade ESSs have a significantly different clinical behaviour
from high-grade tumors. The therapeutic role of lymphadenec-
tomy and adjuvant therapy remains unclear. However, our data
suggest that ovarian-sparing surgeries may be considered in
younger patients with early-stage disease.
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